Cited 0 times in
Expression of fas ligand in human hepatoma cell lines: role of hepatitis B virus X (HBX) in induction of fas ligand
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김세종 | - |
dc.contributor.author | 김호근 | - |
dc.contributor.author | 박전한 | - |
dc.contributor.author | 신전수 | - |
dc.date.accessioned | 2020-01-10T02:04:20Z | - |
dc.date.available | 2020-01-10T02:04:20Z | - |
dc.date.issued | 1999 | - |
dc.identifier.issn | 0020-7136 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/173848 | - |
dc.description.abstract | It has been postulated that tumor cells expressing Fas ligand (FasL) can evade immune surveillance by inducing apoptosis in T cells expressing Fas. In this study, we investigated FasL expression in 13 human hepatoma cell lines. Strong FasL expression was detected by reverse transcription-polymerase chain reaction or immunofluorescence in Hep G2.2.15, in which the hepatitis-B-virus (HBV) genome was transfected, and in SNU-354, which showed HBx transcripts. To determine the biological activity of FasL, Hep G2.2. 15 was co-cultured with MOLT-4, T-cell-leukemia cells. Hep G2.2.15 induced apoptosis in MOLT-4 and this was inhibited by the antagonistic anti-Fas antibody, ZB4. For further analysis of the role of HBx in the induction of FasL, PLC/PRF/5 cells were transfected transiently with the HBV genome, or HBx, or the frameshift mutant of HBx. In PLC/PRF/5 cells transfected with the HBV genome or HBx but not in cells transfected with the frameshift mutant of HBx, FasL expression was detected. Our data suggest that HBx plays a role in the induction of FasL in hepatoma cells and in the escape from immune surveillance. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Wiley-Liss | - |
dc.relation.isPartOf | International Journal of Cancer | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Apoptosis/physiology* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/metabolism* | - |
dc.subject.MESH | Carcinoma, Hepatocellular/virology | - |
dc.subject.MESH | Fas Ligand Protein | - |
dc.subject.MESH | Hepatitis B virus/genetics | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms/metabolism* | - |
dc.subject.MESH | Liver Neoplasms/virology | - |
dc.subject.MESH | Membrane Glycoproteins/metabolism | - |
dc.subject.MESH | Membrane Glycoproteins/physiology* | - |
dc.subject.MESH | Trans-Activators/genetics | - |
dc.subject.MESH | Trans-Activators/physiology* | - |
dc.subject.MESH | Transfection | - |
dc.subject.MESH | Tumor Cells, Cultured | - |
dc.subject.MESH | Tumor Escape | - |
dc.title | Expression of fas ligand in human hepatoma cell lines: role of hepatitis B virus X (HBX) in induction of fas ligand | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Microbiology (미생물학교실) | - |
dc.contributor.googleauthor | Eui-Cheol Shin | - |
dc.contributor.googleauthor | Jeon‐Soo Shin | - |
dc.contributor.googleauthor | Jeon‐Han Park | - |
dc.contributor.googleauthor | Hoguen Kim | - |
dc.contributor.googleauthor | Se‐Jong Kim | - |
dc.identifier.doi | 10.1002/(sici)1097-0215(19990812)82:4<587::aid-ijc19>3.0.co;2-9 | - |
dc.contributor.localId | A00603 | - |
dc.contributor.localId | A01183 | - |
dc.contributor.localId | A01641 | - |
dc.contributor.localId | A02144 | - |
dc.relation.journalcode | J01092 | - |
dc.identifier.eissn | 1097-0215 | - |
dc.identifier.pmid | 10404075 | - |
dc.contributor.alternativeName | Kim, Se Jong | - |
dc.contributor.affiliatedAuthor | 김세종 | - |
dc.contributor.affiliatedAuthor | 김호근 | - |
dc.contributor.affiliatedAuthor | 박전한 | - |
dc.contributor.affiliatedAuthor | 신전수 | - |
dc.citation.volume | 82 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 587 | - |
dc.citation.endPage | 591 | - |
dc.identifier.bibliographicCitation | International Journal of Cancer, Vol.82(4) : 587-591, 1999 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.